Funding to accelerate clinical validation of AvenCell's proprietary Universal Switchable CAR-T cell therapy platform, for the treatment of a wide range of hematologic malignancies and auto-immune diseases New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland...
AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings
Seaking AlphaSeeking Alpha / Seaking Alpha 6 hours ago 1 Views
Comments